Results 241 to 250 of about 74,631 (338)

Early‐Onset Movement Disorder Syndrome Caused by Biallelic Variants in PDE1B Encoding Phosphodiesterase 1B

Movement Disorders, EarlyView.
Abstract Background Breakdown of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in basal ganglia cells through hydrolysis of diesteric bonds, primarily by PDE10A and PDE1B, is essential for normal human movement. While biallelic loss‐of‐function variants in PDE10A are known to cause hyperkinetic movement disorders, the ...
Tomer Poleg, Noam Hadar, Eyal Kristal, Nicola Y. Roberts, Vadim Dolgin, Ilana Aminov, Amit Safran, Nadav Agam, Matan Jean, Ofek Freund, Eamonn G. Sheridan, James A. Poulter, Michelle L. Thompson, Yusra Algoos, Salma Al‐Qahtani, Lama AlAbdi, Sateesh Maddirevula, Verity Hartill, Henry Houlden, Reza Maroofian, Amit Nahum, Ohad S. Birk   +21 more
wiley   +1 more source

Reconsidering dopaminergic modulation in Alzheimer's disease: A case for levodopa/carbidopa as a disease-modifying agent. [PDF]

Alzheimers Dement
Nobili A, D'Amelio M.
europepmc   +1 more source

A Convergent Pathway for Stimulation‐Induced Dyskinesia Following Deep Brain Stimulation

Movement Disorders, EarlyView.
Abstract Background Stimulation‐induced dyskinesias (SID) from deep brain stimulation (DBS) of the subthalamic nucleus (STN) and globus pallidus internus (GPi) are uncommon; however, they are increasingly recognized. Once considered transient and indicative of effective neuromodulation, SID are now seen as potential therapy‐limiting side effects, akin ...
Joshua K. Wong, Andreas Horn, Erik H. Middlebrooks, Matthew R. Burns, Michael S. Okun   +4 more
wiley   +1 more source

Innovations in Parkinson's Disease: Strategies and Novel Technologies. [PDF]

Cureus
Sha R, Dabus MA, Torres-Russotto DR, Bhakuni N, Dabus GC.   +4 more
europepmc   +1 more source

Adult‐Onset BPAN: An Atypical Presentation Mimicking Early‐Onset Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Mariana H.G. Monje, Padmaja Vittal, Ignacio Juan Keller Sarmiento, Lisa Kinsley, Dimitri Krainc, Niccolò E. Mencacci   +5 more
wiley   +1 more source

Low/High Multi‐Frequency Stimulation of the Subthalamic Nucleus Improves Verbal Fluency Maintaining Motor Control in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background High frequency deep brain stimulation of the subthalamic nucleus (STN‐DBS) is a well‐established therapy for Parkinson's disease (PD) motor symptoms, however, its effect on non‐motor symptoms is controversial. Low frequency DBS can improve cognition, but its effects on motor functions are detrimental.
Lucia Ricciardi, Francescopaolo Cucinotta, Elena Pegolo, Arturo Abundes‐Corona, Bryony Ishihara, Israt Hossain, Zimi Sawacha, Michael Hart, Erlick Pereira, Francesca Morgante, Alfonso Fasano   +10 more
wiley   +1 more source

Revamping Parkinson's disease therapy using PLGA-based drug delivery systems. [PDF]

NPJ Parkinsons Dis
Lababidi JM, Azzazy HME.
europepmc   +1 more source

Effect of Levodopa and Carbidopa on Recovery of Visual Function in Patients With Nonarteritic Anterior Ischemic Optic Neuropathy of Longer Than Six Months?? Duration

, 1996
Lyn A. Sedwick
openalex   +1 more source

Disease‐Modifying Trials in Treated Parkinson's Disease: “Stable Treated” Does Not Equate with Biological Stability

Movement Disorders, EarlyView.
Abstract Traditionally, clinical trials of putative disease‐modifying therapies in Parkinson's disease have enrolled untreated patients at the earliest clinical stages of their disease. Due to a number of challenges inherent with this approach, there has been a recent move to a different study design, enrolling patients who are already taking “stable ...
M. Maral Mouradian, A. Jon Stoessl, Anthony E. Lang   +2 more
wiley   +1 more source